Ishita Drugs & Industries Ltd (524400)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 3 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 28 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Ishita Drugs & Industries Ltd reported Q2 FY27 results on 3 Nov 2026: revenue ₹3.0 Cr (-1.2% year on year, -3.6% on the previous quarter), and net profit ₹0.2 Cr (+14.9% year on year); the operating margin was 5.4%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹3.0 | -1.2% | -3.6% |
| செயல்பாட்டு லாபம் | ₹0.2 | -9.6% | -48.9% |
| நிகர லாபம் | ₹0.2 | +14.9% | -30.1% |
| EPS (₹) | 0.54 | +14.9% | -29.9% |
| செயல்பாட்டு லாப வரம்பு | 5.4% | — | — |
- லாபம் அதன் சொந்தப் போக்கை விட +64% மேலே
- வரிக்கு முந்தைய லாபத்தில் 74% மற்ற வருமானம் மற்றும் ஒருமுறை கிடைத்த வருமானங்களிலிருந்து வந்தது.
- முக்கிய வணிகத்தை விட லாபம் வேகமாக வளர்ந்தது (முக்கிய லாபம் -63%)
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹0.2 கோடி லாபத்தில், ₹0.1 கோடி (26%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது. முக்கிய லாபம் (செயல்பாட்டு லாபத்தில் வட்டி மற்றும் தேய்மானத்தைக் கழித்தது) YoY அடிப்படையில் -63.1% மாறியுள்ளது.
அதன் சொந்தப் போக்குக்கு எதிராக: நிகர லாபம் ₹0.2 கோடியாக இருந்தது; இது, அதன் சமீபத்திய வளர்ச்சி சுட்டிக்காட்டிய ₹0.1 கோடியுடன் ஒப்பிடும்போது +63.7% ஆகும் (above trend). இது ஒரு புள்ளியியல் அடிப்படை மட்டுமே; ஆய்வாளர் மதிப்பீடு அல்ல.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Ishita Drugs & Industries approved its Q2 FY27 results and provided an update on its manufacturing facility upgradation to comply with Revised Schedule M norms. The company has spent approximately ₹4.88 crore (~41% of net worth) towards building renovations and new block construction. Capex payments made so far total ₹1.90 crore, supported by an initial term loan disbursement of ₹51.90 lakh from HDFC Bank out of a total sanctioned facility of ₹9.75 crore. For H1 FY27, Profit Before Tax stood at ₹51.40 lakh, with Capital Work-in-Progress rising to ₹2.86 crore as of September 30, 2026.
- Nearly ₹488 lakh spent till date on renovation and construction for Revised Schedule M compliance
- Secured term loan of ₹975 lakh from HDFC Bank, with ₹51.90 lakh disbursed so far
- Paid ₹190 lakh towards capital expenditure via advances and invoices
- Capital work-in-progress increased to ₹285.63 lakh as of September 30, 2026, up from ₹174.73 lakh in March 2026
- Half-year Profit Before Tax reported at ₹51.40 lakh
Ishita Drugs & Industries Ltd has scheduled a meeting of its Board of Directors on Tuesday, November 3, 2026. The board will consider and approve the unaudited financial results for the quarter ended September 30, 2026. Additionally, the insider trading window has been closed from October 1, 2026, and will reopen 48 hours post the result announcement. In Q1 FY27 (Jun 2026), the company posted a net profit of ₹0.23 crore on revenue of ₹3.15 crore.
- Board meeting scheduled on Tuesday, November 3, 2026
- Agenda includes consideration and approval of unaudited results for the quarter ended September 30, 2026
- Trading window closed from Thursday, October 1, 2026 until 48 hours after financial results disclosure
Ishita Drugs & Industries has entered into a loan agreement with HDFC Bank Limited to avail credit facilities totaling Rs 11.75 crore. The financing includes a term loan of Rs 9.75 crore and a working capital facility of Rs 2.00 crore. The funds are earmarked for upgrading its manufacturing facility at Sanand, Gujarat, to comply with Revised Schedule M standards. At Rs 11.75 crore, this debt facility is highly material, representing nearly 98% of its TTM revenue of Rs 12 crore and about 98% of its net worth of Rs 12 crore.
- Total credit facility of Rs 11.75 crore executed with HDFC Bank on 22.09.2026
- Facility comprises a Rs 9.75 crore term loan and a Rs 2.00 crore working capital limit
- Proceeds to fund plant upgradation to meet Revised Schedule M pharma compliance at Sanand, Gujarat
- Secured by a first charge on immovable and movable assets at Sanand facility; current outstanding is Nil
Ishita Drugs & Industries Ltd has approved credit facilities totaling ₹11.75 crore from HDFC Bank Ltd. The borrowing comprises a term loan of ₹9.75 crore and a working capital facility of ₹2.00 crore based on HDFC Bank's sanction letter dated September 17, 2026. This is a very significant leverage increase for the micro-cap pharma company, as the facility represents roughly 98% of its TTM revenue (₹12 crore) and matches its net worth of ₹12 crore, shifting its previously debt-free balance sheet.
- Total borrowing approved: ₹11,75,00,000 (₹11.75 crore) from HDFC Bank Limited
- Facility split: ₹9,75,00,000 (₹9.75 crore) Term Loan and ₹2,00,00,000 (₹2.00 crore) Working Capital
- Terms governed by HDFC Bank's Sanction Letter dated September 17, 2026
- Borrowing is within limits approved under Section 180(1)(c) at AGM held on September 30, 2024
Ishita Drugs & Industries Ltd has issued letters providing the weblink to its FY2025-26 Annual Report and AGM Notice to shareholders without registered email addresses. The company's 33rd Annual General Meeting is scheduled to be held on Wednesday, September 30, 2026, at 11:30 AM in Sanand, Gujarat. Physical dispatches to unregistered shareholders were completed via courier on August 27, 2026, based on the record cut-off date of August 21, 2026.
- 33rd Annual General Meeting scheduled for September 30, 2026, at 11:30 AM
- Letters containing the FY26 Annual Report weblink dispatched to unregistered shareholders on August 27, 2026
- Shareholder email registration record cut-off date fixed as August 21, 2026
Ishita Drugs & Industries Ltd has submitted its Annual Report for FY 2025-26 pursuant to Regulation 34 of SEBI LODR Regulations. The 33rd Annual General Meeting (AGM) is scheduled for September 30, 2026, at Sanand, Gujarat. The key agenda items include the adoption of FY26 financial statements, re-appointment of the statutory auditor, re-appointment of director Mrs. Abha Agrawal, and approval of material related-party transactions exceeding 10% of annual turnover with Ishita Pharmaceuticals and Anvi Lifesciences.
- 33rd Annual General Meeting scheduled for September 30, 2026, at 11:30 AM
- Register of Members and Share Transfer books to remain closed from September 24, 2026, to September 30, 2026
- Seeking shareholder approval for related-party transactions exceeding 10% of annual turnover with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited
- Proposed re-appointment of M/s Jaymin Shah & Associates as statutory auditors for one year
Ishita Drugs has announced a major manufacturing facility upgradation to comply with Revised Schedule M standards, involving a total commitment of approximately Rs 10 crore. To date, the company has spent Rs 4.35 crore on civil works and a new warehouse, with another Rs 5.65 crore in equipment orders issued. This project is highly material, representing approximately 67% of the company's TTM revenue of Rs 15 crore and 83% of its net worth. The board also approved the re-appointment of promoter Mrs. Abha Agrawal as a director and is currently negotiating with banks for project financing.
- Rs 4.35 crore already spent on renovation of existing buildings and construction of a new warehouse block.
- Rs 5.65 crore in capital contracts and orders issued for various utilities and equipment.
- Total project commitment of ~Rs 10 crore represents ~67% of TTM revenue (Rs 15 Cr).
- Re-appointment of Mrs. Abha Agrawal as Non-Executive Director notwithstanding her attaining the age of 75 years.
- Company is actively negotiating with banks to raise funds for financing the remaining upgradation project.
Ishita Drugs & Industries has announced a major manufacturing facility upgradation project to comply with Revised Schedule M standards. The company has already spent Rs 4.35 crore on renovation and new construction, with an additional Rs 5.65 crore in capital contracts already issued. This total commitment of Rs 10 crore is highly significant, representing approximately 67% of the company's TTM revenue of Rs 15 crore. The company is currently negotiating with banks to secure financing for the project.
- Rs 4.35 crore already spent on renovation of existing buildings and construction of new blocks
- Rs 5.65 crore in capital contracts and orders issued for utilities and equipment
- Total project visibility of Rs 10 crore represents ~67% of TTM revenue (Rs 15 cr)
- Upgradation project is aimed at compliance with Revised Schedule M manufacturing standards
- Board approved re-appointment of promoter Mrs. Abha Agrawal as Non-Executive Director
Ishita Drugs & Industries has announced a significant manufacturing facility upgrade to comply with Revised Schedule M standards. The company has already spent ₹4.35 crore on construction and has issued capital contracts worth ₹5.65 crore for equipment and utilities. This total project outlay of ₹10 crore is highly material, representing approximately 67% of the company's TTM revenue of ₹15 crore. The board also approved Q1 FY27 results and is currently negotiating with banks to secure funding for the project.
- ₹435 lakh (₹4.35 cr) already spent towards renovation and construction of new blocks
- ₹565 lakh (₹5.65 cr) in capital contracts and orders issued for utilities and equipment
- Total project visibility of ₹10 cr represents ~67% of TTM revenue and ~43% of market cap
- Construction of a new warehouse block has been completed as part of the ongoing upgrade
- Board approved re-appointment of promoter-director Mrs. Abha Agrawal post attaining age 75
Ishita Drugs & Industries Ltd has scheduled a board meeting for August 8, 2026, to approve its unaudited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of Rs 22 Cr and TTM revenue of Rs 15 Cr. Investors will be monitoring for a potential recovery in quarterly revenue, which declined from Rs 5.4 Cr in June 2025 to Rs 3.06 Cr in March 2026. The trading window for designated persons has been closed since July 1, 2026, as per SEBI regulations.
- Board meeting scheduled for August 8, 2026, to approve Q1 FY27 results
- Trading window closed from July 1, 2026, until 48 hours after result declaration
- Company reported TTM revenue of Rs 15 Cr and TTM PAT of Rs 1 Cr
- Operating profit margin (OPM) stands at 5.2% as per latest annual data
- Promoter holding remains stable at 50.04% as of June 2026
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
